These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 3223284)

  • 1. Oral therapeutic system delivering a water insoluble drug: N-(4-[2-(3-methylpyrazole-1-carbonamide)ethyl]-benzenesulfonyl)N - cyclohexylurea (SPC-5002).
    Janicki S; Jedras Z; Sawicki W
    Acta Pharm Hung; 1988 Jul; 58(4):145-51. PubMed ID: 3223284
    [No Abstract]   [Full Text] [Related]  

  • 2. [Clinical study of a new oral hypoglycemic agent: glypentide (UR-661)].
    Calvet JM; Matarrodona M; Bordas R
    Rev Iber Endocrinol; 1974; 21(124):347-62. PubMed ID: 4453782
    [No Abstract]   [Full Text] [Related]  

  • 3. [Therapy with oral antidiabetic agents -- special considerations in the case of coronary heart disease].
    Nauck MA; Matthaei S
    Dtsch Med Wochenschr; 2005 Apr; 130(17):1091-6. PubMed ID: 15841424
    [No Abstract]   [Full Text] [Related]  

  • 4. [Derivatives of pyrazole-l-carboxylic acid. VII. Synthesis and hypoglycemic properties of various N-(4-[2-(alkyl-2-pyrazoline-1-carbonamido)-ethyl]-benzenesulfonyl)-N'-cyclohexylurea].
    Brzozowski Z; Magiełka S; Wójcikowski C
    Acta Pol Pharm; 1983; 40(2):134-8. PubMed ID: 6659996
    [No Abstract]   [Full Text] [Related]  

  • 5. Studies on oral hypoglycemia agents -- blood levels and hypoglycemic effects of sulfonylurea compounds--.
    Fukuchi H; Tsukiai S; Kumagai M; Kitaura T
    Hiroshima J Med Sci; 1977 Dec; 26(4):269-76. PubMed ID: 615173
    [No Abstract]   [Full Text] [Related]  

  • 6. [Clinical experience with RO 6-4563 (Glibornuride) (a new oral hypoglycemic agent)].
    Rodríguez-Miñón JL; Herrera Pombo JL; Marrón JA
    Rev Clin Esp; 1971 Dec; 123(5):439-42. PubMed ID: 5160567
    [No Abstract]   [Full Text] [Related]  

  • 7. Formulation and biological evaluation of glimepiride-cyclodextrin-polymer systems.
    Ammar HO; Salama HA; Ghorab M; Mahmoud AA
    Int J Pharm; 2006 Feb; 309(1-2):129-38. PubMed ID: 16377107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of a new hypoglycemic agent SPC-703.
    Jakubowski Z; Angielski S
    Pol J Pharmacol Pharm; 1980; 32(2):165-72. PubMed ID: 7454622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [New compounds and reactions of sulfonamides with amines. XV. Synthesis and hypoglycemic activity of some derivatives of N-(benzenesulfonyl)-3,5-diethyl-5-methyl-2-pyrazoline-1-carbonamide].
    Brzozowski Z; Dekarz B; Angielski S; Wójcikowski C
    Acta Pol Pharm; 1976; 33(3):301-5. PubMed ID: 941694
    [No Abstract]   [Full Text] [Related]  

  • 10. Current status of oral agents in diabetes.
    Kilo C
    Compr Ther; 1982 Dec; 8(12):26-32. PubMed ID: 7160161
    [No Abstract]   [Full Text] [Related]  

  • 11. Implication of inclusion complexation of glimepiride in cyclodextrin-polymer systems on its dissolution, stability and therapeutic efficacy.
    Ammar HO; Salama HA; Ghorab M; Mahmoud AA
    Int J Pharm; 2006 Aug; 320(1-2):53-7. PubMed ID: 16701974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Use of oral hypoglycemic agents in diabetic children].
    Otto-Buczkowska E
    Pol Tyg Lek; 1973; 28(24):904-7. PubMed ID: 4724902
    [No Abstract]   [Full Text] [Related]  

  • 13. Oral hypoglycemic agents: the pharmacological basis of their clinical use.
    Davidoff F
    R I Med J; 1973 Oct; 56(10):409-14. PubMed ID: 4518221
    [No Abstract]   [Full Text] [Related]  

  • 14. [The use of oral antidiabetics].
    Kangas T
    Duodecim; 1974; 90(4):282-94. PubMed ID: 4603906
    [No Abstract]   [Full Text] [Related]  

  • 15. When--and how--to use an oral agent.
    Shuman CR
    Med Times; 1980 May; 108(5):77-81, 85-6. PubMed ID: 7374409
    [No Abstract]   [Full Text] [Related]  

  • 16. Biotransformation of a new hypoglycemic agent, N-(p-toluenesulfonyl)-5-methyl-2-pyrazoline-1-carbonamide (SPC-703) in humans and rats.
    Jakubowski Z; Angielski S
    Pol J Pharmacol Pharm; 1980; 32(1):37-46. PubMed ID: 7454610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Therapeutic trial of a new antidiabetic with vascular action: 1702 SE].
    Jaillard J; Warembourg H
    Lille Med; 1972 Oct; 17(9):Suppl 6:1332-6. PubMed ID: 4657429
    [No Abstract]   [Full Text] [Related]  

  • 18. [Clinical evaluation of glypidizine, a new oral hypoglycemic agent].
    Domingo Gutiérrez AJ; Fernández-Cruz A
    Rev Iber Endocrinol; 1973; 20(117):289-303. PubMed ID: 4581992
    [No Abstract]   [Full Text] [Related]  

  • 19. [Risks of peroral treatment of diabetes].
    Rybka J
    Vnitr Lek; 1983 Nov; 29(11):1114-8. PubMed ID: 6659388
    [No Abstract]   [Full Text] [Related]  

  • 20. [Oral antidiabetics today].
    Aro A
    Duodecim; 1981; 97(12):837-47. PubMed ID: 7297451
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.